Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients

NCT02744209 · clinicaltrials.gov ↗
TERMINATED
Status
17
Enrollment
OTHER
Sponsor class

Stopped Low accrual

Conditions

Sponsor

Mayo Clinic

Collaborators